Research analysts covering Telomir Pharmaceuticals.
Recent press releases and 8-K filings for TELO.
Telomir Pharmaceuticals Reports Discovery Regarding Telomir-1 and Triple-Negative Breast Cancer Cells
TELO
New Projects/Investments
- Telomir Pharmaceuticals, Inc. announced new findings on October 8, 2025, demonstrating that its compound, Telomir-1, significantly reduces the survival of aggressive triple-negative breast cancer (TNBC) cells in laboratory studies.
- The discovery indicates that Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation.
- This mechanism is particularly relevant as aggressive cancer cells are highly dependent on iron, suggesting Telomir-1 may selectively target cancer cells while potentially sparing healthy tissue.
- The company plans to expand these studies to include additional cancer types, such as pancreatic and leukemia models, and conduct further animal studies in preparation for an Investigational New Drug (IND) submission.
Oct 8, 2025, 8:01 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more